Wednesday, July 30, 2014 Last update: 4:03 AM
FreshNews.com - All Company Technology News Since 1996

PharmAthene, Inc.

News articles for PharmAthene, Inc.:

Monday, June 9, 2014

  • PharmAthene Granted U.S. Patent For Recombinant Bioscavenger
    ANNAPOLIS, Md., June 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells. PharmAthene is initially developing ... read more

Wednesday, June 4, 2014

Thursday, May 29, 2014

Thursday, May 8, 2014

  • PharmAthene Reports First Quarter 2014 Financial And Operational Results
    ANNAPOLIS, Md., May 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the first quarter of 2014. For the three months ended March 31, 2014, PharmAthene recognized revenue of approximately $3.7 million, ... read more

Monday, April 7, 2014

  • PharmAthene Updates Status Of SparVax® Anthrax Vaccine Contract
    ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through ... read more

Tuesday, April 1, 2014

Tuesday, March 11, 2014

  • PharmAthene Reports Year-End 2013 Financial And Operational Results
    ANNAPOLIS, Md., March 11, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the year ended December 31, 2013. "We remain focused on advancing our core biodefense programs, including addressing the SparVax(®) clinical ... read more

Monday, March 10, 2014